GANNON STEVEN

SEC Form 4 insider trading activity

GANNON STEVEN has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 13, 2026.

On the most recent filing, GANNON STEVEN is listed as Director at Xenon Pharmaceuticals Inc. Inside the rolling window, GANNON STEVEN reported no open-market purchases and 1 open-market sale totaling $641K in XENE.

Companies traded

Other insiders at XENE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$641K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
XENE
GANNON STEVEN
Sale$641KAug 13SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has GANNON STEVEN made?

GANNON STEVEN has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.

Which companies does GANNON STEVEN trade?

GANNON STEVEN has filed SEC Form 4 disclosures for 1 company, including XENE.

When was GANNON STEVEN's most recent SEC Form 4 filing?

GANNON STEVEN's most recent SEC Form 4 filing on Tracefour is dated Aug 13, 2026.

What is GANNON STEVEN's total buy and sell value in the current window?

Inside the rolling retention window, GANNON STEVEN bought $0 and sold $641K based on SEC Form 4 filings.

What was GANNON STEVEN's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 10,000 XENE shares on 2026-08-11, worth $641K, per SEC Form 4 filings.